Unlocking Hope for Cancer Patients Using PDT

AGREEMENT TO DEVELOP AND FUND PHOTOSOFT™ FOR HPV HPV IS THE MOST COMMON SEXUALLY TRANSMITTED INFECTION GLOBALLY¹ In all females, the highest (HPV) prevalence is found in Asian regions² HPV distribution profile in women² CHALLENGES IN TREATMENT Viral persistence and recurrence Limited effectiveness of current treatments topical medications, surgical and ablative therapies 57.7% 44.4% 42.2% 21.4% 3.7% Eastern Asia Central & Sub-Saharan Southern Asia Africa Eastern Europe Western Europe • Leads to anogenital and oropharyngeal cancers • Limited access and high cost of HPV vaccination Vaccine hesitancy 14 • DR.INB TO DEVELOP AND FUND PHOTOSOFT FOR THE TREATMENT OF HPV Undertake and fund evaluation plus in-human Proof-of-Concept clinical trials to test patient safety and efficacy ⚫ Dr.inB is a leading developer of PDT treatments in South Korea backed by Hanlim Pharma. Co., Ltd. • Collaboration provides accelerated pathway to demonstrate clinical potential of Photosoft in infectious diseases like HPV . Invion retains all rights to Photosoft and any new IP from the collaboration https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer 2 https://www.sciencedirect.com/science/article/abs/pii/S0264410X12010808 INVION

View entire presentation